Cited by 1,547Lipoproteins and Cardiovascular HealthCholesterol and Lipid MetabolismParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 47 of the 50 references it cites were found in a registry or an index.

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Desforges, Jane F., Gordon, David J., Rifkind, Basil M.·1989·New England Journal of Medicine

DOI 10.1056/nejm198911093211907

Open this paper in CoChat — free account

Abstract

DESPITE early observations suggesting an inverse relation between serum levels of high-density lipoprotein (HDL) cholesterol and coronary disease,1 2 3 the possible protective role of HDL in atherogenesis received little attention until its "rediscovery" by Miller and Miller4 in 1975 and the publication of confirmatory results from the Honolulu,5 Framingham,6 and Tromsø7 heart studies in 1976 and 1977. In the ensuing decade, research into the biochemistry, metabolism, epidemiology, and genetics of HDL has expanded rapidly, but many questions remain unanswered. The recent publication of the results of the Helsinki Heart Study8 , 9 — in which simultaneous 11 percent increases in HDL and reductions . . .

Integrity signals

Registry

Crossref · 10.1056/nejm198911093211907

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

High density lipoprotein as a protective factor against coronary heart disease
Gordon, T., Castelli, W. P., Hjortland, M. C., Kannel, W. B., & Dawber, T. R. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90874-9 · Cited by 5,059
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
Self-citation
PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE
Miller, G. J., & Miller, N. E. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92376-4 · Cited by 2,621
Incidence of Coronary Heart Disease and Lipoprotein Cholesterol Levels
Castelli, W. P. (1986) · JAMA · doi:10.1001/jama.256.20.2835 · Cited by 2,512
Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
Goodman, D. S. (1988) · Archives of Internal Medicine · doi:10.1001/archinte.1988.00380010040006 · Cited by 2,458
The plasma lecithin:cholesterol acyltransferase reaction
Glomset, J. A. (1968) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43114-1 · Cited by 2,396
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Beneficial Effects of Combined Colestipol-Niacin Therapy on Coronary Atherosclerosis and Coronary Venous Bypass Grafts
Blankenhorn, D. H. (1987) · JAMA · doi:10.1001/jama.1987.03390230069027 · Cited by 1,654
Comparison of effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on plasma lipids and lipoproteins in man.
Mattson, F. H., & Grundy, S. M. (1985) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34389-3 · Cited by 1,354

Show all 50 references

Research works printed but not linked: 10

Gofman, 1954, Plasma, 2, 413
Hulley, 1977, JAMA, 238, 2269, 10.1001/jama.1977.03280220037017 · DOI
Ernst, 1980, Circulation, 62, IV-41
Sacks, 1985, JAMA, 254, 1337, 10.1001/jama.1985.03360100087019 · DOI
Davis, 1980, Circulation, 62, IV-24
Enger, 1979, Artery, 5, 170
Levy, 1987, Circulation, 76, IV-167
Superko, 1986, JAMA, 256, 2714, 10.1001/jama.1986.03380190084030 · DOI
Hunninghake D, Gordon DJ, Tamir I, Rifkind BM. Management of hyperlipidemia. In: Pradhan SN, Maickel RP, Dutta SN, eds. Textbook of pharmacology. Bethesda, Md.: SP Press International, 1986:617–33.
Castelli, 1986, JAMA, 256, 2835, 10.1001/jama.1986.03380200073024 · DOI

Sorted by citations

Atherosclerosis
Lusis, A. J. (2000) · Nature · doi:10.1038/35025203 · Cited by 4,880
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel
Borén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
Effect of dietary fatty acids on serum lipids and lipoproteins. A meta-analysis of 27 trials
Mensink, R. P., & Katan, M. B. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.8.911 · Cited by 1,477
“026 mmol/l) decrease in HDL cholesterol.(56) A causal relation between changes in HDL cholesterol and changes in risk is credible but not proven.”
Background
Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
Rubin, E. M., Krauss, R. M., Spangler, E. A., Verstuyft, J. G., & Clift, S. (1991) · Nature · doi:10.1038/353265a0 · Cited by 985
Prevalence and Characteristics of the Metabolic Syndrome in Women with Polycystic Ovary Syndrome
Apridonidze, T., Essah, P. A., Iuorno, M. J., & Nestler, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1045 · Cited by 931
Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL
Vaisar, T., Pennathur, S., Green, P. S., Gharib, S. A., Hoofnagle, A. N., Cheung, M. C., Byun, J., Vuletic, S., Kassim, S., Singh, P., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci26206 · Cited by 942
Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation
Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 862
A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism
Rigotti, A., Trigatti, B. L., Penman, M., Rayburn, H., Herz, J., & Krieger, M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.23.12610 · Cited by 860
The Effect of Polyphenols in Olive Oil on Heart Disease Risk Factors: A Randomized Trial
Covas, M.-I., Nyyssönen, K., Poulsen, H. E., Kaikkonen, J., Zunft, H.-J. F., Kiesewetter, H., Gaddi, A., de la Torre, R., Mursu, J., Bäumler, H., et al. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-5-200609050-00006 · Cited by 758
“026-mmol/L (1-mg/dL) increase in HDL cholesterol levels has been associated with a 2% to 3% decrease in CHD risk (27).”
Background
High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase
Yuhanna, I. S., Zhu, Y., Cox, B. E., Hahner, L., Osborne-Lawrence, S. L., Lu, P., Marcel, Y. L., Anderson, R. G. W., Mendelsohn, M. E., Hobbs, H. H., et al. (2001) · Nature Medicine · doi:10.1038/89986 · Cited by 753
“Bovine eNOS cDNA was transiently transfected into SR-BI–deficient CHO cells and CHO cells stably transformed with murine SR-BI (refs”
Method
Dietary fat and risk of coronary heart disease in men: cohort follow up study in the United States
Ascherio, A., Rimm, E. B., Giovannucci, E. L., Spiegelman, D. L., Stampfer, M. J., & Willett, W. C. (1996) · BMJ · doi:10.1136/bmj.313.7049.84 · Cited by 733
ATP-Binding Cassette Transporters and HDL Suppress Hematopoietic Stem Cell Proliferation
Yvan‐Charvet, L., Pagler, T. A., Gautier, E. L., Avagyan, S., Siry, R., Han, S., Welch, C. L., Wang, N., Randolph, G. J., Snoeck, H. W., et al. (2010) · Science · doi:10.1126/science.1189731 · Cited by 724
Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels
Kozarsky, K., Donahee, M. H., Rigotti, A., Iqbal, S. N., Edelman, E. R., & Krieger, M. (1997) · Nature · doi:10.1038/387414a0 · Cited by 697
Scavenger Receptor BI Promotes High Density Lipoprotein-mediated Cellular Cholesterol Efflux
Ji, Y. I., Jian, B., Wang, N., Sun, Y., Moya, M. D. L. L., Phillips, M. C., Rothblat, G. H., Swaney, J. B., & Tall, A. R. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.34.20982 · Cited by 694
High Density Lipoproteins and Arteriosclerosis
von Eckardstein, A., Nofer, J., & Assmann, G. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.1.13 · Cited by 696
Macrophage phenotypes in atherosclerosis
Colin, S., Chinetti‐Gbaguidi, G., & Staels, B. (2014) · Immunological Reviews · doi:10.1111/imr.12218 · Cited by 657
“Epidemiological studies have consistently demonstrated an inverse correlation between plasma high density lipoprotein cholesterol (HDL-C) and the risk of coronary artery disease and its thrombotic complications (136, 137).”
Background
Cholesterol Reduction in Cardiovascular Disease — Clinical Benefits and Possible Mechanisms
Levine, G. N., Keaney, J. F., & Vita, J. A. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502233320807 · Cited by 673
Endothelial and Antithrombotic Actions of HDL
Mineo, C., Deguchi, H., Griffin, J. H., & Shaul, P. W. (2006) · Circulation Research · doi:10.1161/01.res.0000225982.01988.93 · Cited by 663
“(2) Based on studies of mimetics of apoA-I, HDL prevents eNOS uncoupling by LDL, which favors O2 .”
Background
Plasma high density lipoproteins. Metabolism and relationship to atherogenesis.
Tall, A. R. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114722 · Cited by 650
HDL Cholesterol and Protective Factors in Atherosclerosis
Assmann, G., & Gotto, A. M. (2004) · Circulation · doi:10.1161/01.cir.0000131512.50667.46 · Cited by 637
The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis
Kuivenhoven, J. A., Jukema, J. W., Zwinderman, A. H., de Knijff, P., McPherson, R., Bruschke, A. V. G., Lie, K. I., & Kastelein, J. J. P. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380203 · Cited by 623
Protein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 642
“In the case of HDL-cholesterol levels, they have shown an inverse correlation with the risk of cardiovascular-related diseases [102].”
Background
Healthy Traditional Mediterranean Diet: An Expression of Culture, History, and Lifestyle
Trichopoulou, A., & Λάγιου, Π. (2009) · Nutrition Reviews · doi:10.1111/j.1753-4887.1997.tb01578.x · Cited by 629
HDL and arteriosclerosis: beyond reverse cholesterol transport
Nofer, J., Kehrel, B. E., Fobker, M., Levkau, B., Assmann, G., & von Eckardstein, A. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00651-7 · Cited by 596
Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.
Zhong, S., Sharp, D. S., Grove, J., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 579
“Moreover, the general inverse relationship between HDL levels and CHD is observed in the elderly (4), and was seen in this study (Fig.”
Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.
Plump, A. S., Scott, C., & Breslow, J. L. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.20.9607 · Cited by 569
Regulation of Endothelial Nitric Oxide Synthase: Location, Location, Location
Shaul, P. W. (2002) · Annual Review of Physiology · doi:10.1146/annurev.physiol.64.081501.155952 · Cited by 545
Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study
Leng, G. C., Fowkes, F. G. R., Alexander, L. E. E., Dunbar, J., Housley, E., & Ruckley, C. V. (1996) · BMJ · doi:10.1136/bmj.313.7070.1440 · Cited by 525
Charting the Fate of the “Good Cholesterol”: Identification and Characterization of the High-Density Lipoprotein Receptor SR-BI
Krieger, M. (1999) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.68.1.523 · Cited by 517
Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology
Trigatti, B. L., Rayburn, H., Viñals, M., Braun, A., Miettinen, H. E., Penman, M., Hertz, M., Schrenzel, M. D., Amigo, L., Rigotti, A., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.16.9322 · Cited by 504
A novel endothelial-derived lipase that modulates HDL metabolism
Jaye, M., Lynch, K. J., Krawiec, J., Marchadier, D., Maugeais, C., Doan, K., South, V., Amin, D., Perrone, M., & Rader, D. J. (1999) · Nature Genetics · doi:10.1038/7766 · Cited by 427
VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial
Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490
In vivo protection against endotoxin by plasma high density lipoprotein.
Levine, D. M., Parker, T. S., Donnelly, T. M., Walsh, A., & Rubin, A. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12040 · Cited by 485
Apolipoprotein A-I and B Levels and the Risk of Ischemic Heart Disease During a Five-Year Follow-up of Men in the Que´bec Cardiovascular Study
Lamarche, B., Moorjani, S., Lupien, P. J., Cantin, B., Bernard, P.-M., Dagenais, G. R., & Despre´s, J.-P. (1996) · Circulation · doi:10.1161/01.cir.94.3.273 · Cited by 476
Randomized clinical trials on the effects of dietary fat and carbohydrate on plasma lipoproteins and cardiovascular disease
Sacks, F. M., & Katan, M. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00987-1 · Cited by 477
Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women
Liu, S., Manson, J. E., Stampfer, M. J., Holmes, M. D., Hu, F. B., Hankinson, S. E., & Willett, W. C. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.3.560 · Cited by 454
Increased Inflammatory Gene Expression in ABC Transporter–Deficient Macrophages: Free Cholesterol Accumulation, Increased Signaling via Toll-Like Receptors, and Neutrophil Infiltration of Atherosclerotic Lesions
Yvan-Charvet, L., Welch, C., Pagler, T. A., Ranalletta, M., Lamkanfi, M., Han, S., Ishibashi, M., Li, R., Wang, N., & Tall, A. R. (2008) · Circulation · doi:10.1161/circulationaha.108.793869 · Cited by 439
Dietarytrans fatty acids: effects on plasma lipids and lipoproteins of healthy men and women
Judd, J., Clevidence, B., Muesing, R. A., Wittes, J. T., Sunkin, M. E., & Podczasy, J. J. (1994) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/59.4.861 · Cited by 457
“linked to elevated risk of cardiovascular disease ( 32 ), little is”
Background
Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoproteins in humans.
Zock, P. L., & Katan, M. (1992) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41530-5 · Cited by 440
The Role of the High-Density Lipoprotein Receptor SR-BI in the Lipid Metabolism of Endocrine and Other Tissues
Rigotti, A., Miettinen, H. E., & Krieger, M. (2003) · Endocrine Reviews · doi:10.1210/er.2001-0037 · Cited by 435
Treatment With Dietary trans10cis12 Conjugated Linoleic Acid Causes Isomer-Specific Insulin Resistance in Obese Men With the Metabolic Syndrome
Risérus, U., Arner, P., Brismar, K., & Vessby, B. O. (2002) · Diabetes Care · doi:10.2337/diacare.25.9.1516 · Cited by 438
“cholesterol is an independent cardiovascular risk factor (33), the current reduc-”
Background
The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism
Godsland, I. F., Crook, D., Simpson, R., Proudler, T., Felton, C., Lees, B., Anyaoku, V., Devenport, M., & Wynn, V. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011153232003 · Cited by 417
Perspectives and opportunities for nanomedicine in the management of atherosclerosis
Lobatto, M. E., Fuster, V., Fayad, Z. A., & Mulder, W. J. M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3578 · Cited by 423
“One of the main therapeutic targets in atherosclerosis is HDL, which is an endogenous lipidic nanoparticle (7–13 nm in size), as there is an inverse relationship between serum HDL levels and the risk of coronary heart diseas”
Background
High-Density Lipoproteins and Their Constituent, Sphingosine-1-Phosphate, Directly Protect the Heart Against Ischemia/Reperfusion Injury In Vivo via the S1P 3 Lysophospholipid Receptor
Theilmeier, G., Schmidt, C., Herrmann, J., Keul, P., Schäfers, M. A., Herrgott, I., Mersmann, J., Larmann, J., Hermann, S., Stypmann, J., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.607135 · Cited by 414
Infection and Inflammation‐Induced Proatherogenic Changes of Lipoproteins
Khovidhunkit, W., Memon, R. A., Feingold, K. R., & Grünfeld, C. (2000) · The Journal of Infectious Diseases · doi:10.1086/315611 · Cited by 403
“On the other hand, plasma levels of HDL cholesterol are inversely correlated with the risk of atherosclerosis [26].”
Background
High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
Drew, B. G., Duffy, S. J., Formosa, M. F., Natoli, A. K., Henstridge, D. C., Penfold, S. A., Thomas, W. G., Mukhamedova, N., de Courten, B., Forbes, J. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.843219 · Cited by 443
“Although the magnitude of the plasma glucose reduction might be considered modest, it is likely of clinical significance given (1) that patients were fasted, (2) the short-term nature of the stimulus, and (3) the numerous homeostatic pathways controlling blood glucose.”
Background
High-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL
Zannis, V. I., Chroni, A., & Krieger, M. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0030-4 · Cited by 404
“reacts with the unesterified cholesterol in discoidal and spherical HDL, transferring the 2-acyl group of lecithin or phosphatidylethanolamine to the free hydroxyl residue of cholesterol to generate cholesteryl esters, which are retained in the core of HDL [89, 90].”
Background
High Density Lipoprotein-induced Endothelial Nitric-oxide Synthase Activation Is Mediated by Akt and MAP Kinases
Mineo, C., Yuhanna, I. S., Quon, M. J., & Shaul, P. W. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211394200 · Cited by 390
Prevention of the Angiographic Progression of Coronary and Vein-Graft Atherosclerosis by Gemfibrozil After Coronary Bypass Surgery in Men With Low Levels of HDL Cholesterol
Frick, M. H., Syvänne, M., Nieminen, M. S., Kauma, H., Majahalme, S. K., Virtanen, V., Kesäniemi, Y. A., Pasternack, A. I., & Taskinen, M. (1997) · Circulation · doi:10.1161/01.cir.96.7.2137 · Cited by 389
Association of Cholesteryl Ester Transfer Protein– Taq IB Polymorphism With Variations in Lipoprotein Subclasses and Coronary Heart Disease Risk
Ordovás, J. M., Cupples, L. A., Corella, D., Otvos, J. D., Osgood, D. P., Martinez, A. A., Lahoz, C., Coltell, Ó., Wilson, P. W. F., & Schaefer, E. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.5.1323 · Cited by 379
The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis
Grainger, D. J., Kemp, P. R., Metcalfe, J. C., Liu, A. C., Lawn, R. M., Williams, N. R., Grace, A. A., Schofield, P. M., & Chauhan, A. (1995) · Nature Medicine · doi:10.1038/nm0195-74 · Cited by 377
Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice.
Pászty, C., Maeda, N., Verstuyft, J. G., & Rubin, E. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117412 · Cited by 375
Suppression of Endothelial Cell Apoptosis by High Density Lipoproteins (HDL) and HDL-associated Lysosphingolipids
Nofer, J., Levkau, B., Wolinska, I., Junker, R., Fobker, M., von Eckardstein, A., Seedorf, U., & Assmann, G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103782200 · Cited by 359
Regression of Atherosclerosis Induced by Liver-Directed Gene Transfer of Apolipoprotein A-I in Mice
Tangirala, R. K., Tsukamoto, K., Chun, S. H., Usher, D. C., Puré, E., & Rader, D. J. (1999) · Circulation · doi:10.1161/01.cir.100.17.1816 · Cited by 357
Ten-year cardiovascular mortality in relation to risk factors and abnormalities in lipoprotein composition in Type 2 (non-insulin-dependent) diabetic and non-diabetic subjects
Uusitupa, M. I. J., NISKANEN, L. K., Siitonen, O., Voutilainen, E., & Py�r�l�, K. (1993) · Diabetologia · doi:10.1007/bf00401063 · Cited by 353
“This suggests that the increased risk associated with low HDL may be partially mediated through disturbed VLDL metabolism which is intimately associated with low HDL cholesterol [43].”
Background
Identification of a distinct human high‐density lipoprotein subspecies defined by a lipoprotein‐associated protein, K‐45
Blatter, M.-C., James, R. W., Messmer, S., Barja, F., & Pometta, D. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17620.x · Cited by 347
Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
Oram, J. F., & Yokoyama, S. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37453-8 · Cited by 342
High-density lipoproteins: A consensus statement from the National Lipid Association
Toth, P. P., Barter, P. J., Rosenson, R. S., Boden, W. E., Chapman, M. J., Cuchel, M., D'Agostino, R. B., Davidson, M. H., Davidson, W. S., Heinecke, J. W., et al. (2013) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2013.08.001 · Cited by 336
“Clinical and epidemiologic studies show a robust, inverse association of HDL-C level with CVD risk.(250,251) Moreover, hypercholesterolemic mice with genetically engineered deficiencies in proteins implicated in HDL metabolism have strongly atherosclerotic phenotypes,(252) providing compelling evidence that HDL is a k…”
Background
Gene Transfer and Hepatic Overexpression of the HDL Receptor SR-BI Reduces Atherosclerosis in the Cholesterol-Fed LDL Receptor–Deficient Mouse
Kozarsky, K., Donahee, M. H., Glick, J. M., Krieger, M., & Rader, D. J. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.3.721 · Cited by 337
Troglitazone Inhibits Atherosclerosis in Apolipoprotein E–Knockout Mice
Chen, Z., Ishibashi, S., Perrey, S., Osuga, J.-I., Gotoda, T., Kitamine, T., Tamura, Y., Okazaki, H., Yahagi, N., Iizuka, Y., et al. (2001) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.21.3.372 · Cited by 323
HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells
Feig, J. E., Rong, J. X., Shamir, R., Sanson, M., Vengrenyuk, Y., Liu, J., Rayner, K. J., Moore, K. J., Garabedian, M. J., & Fisher, E. A. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016086108 · Cited by 313
Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis
Rittershaus, C. W., MILLER, D. P., Thomas, L. J., Picard, M. D., Honan, C. M., Emmett, C. D., Pettey, C. L., Adari, H. Y., Hammond, R. A., Beattie, D. T., et al. (2000) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.20.9.2106 · Cited by 308
The emerging role of HDL in glucose metabolism
Drew, B. G., Rye, K.-A., Duffy, S. J., Barter, P., & Kingwell, B. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.235 · Cited by 307
“increased free fatty acid flux, contributing further to deteriorations in the lipid profile (2).”
Background
Targeted mutation reveals a central role for SR-BI in hepatic selective uptake of high density lipoprotein cholesterol
Varban, M. L., Rinninger, F., Wang, N., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Gosselin, M. L., Dixon, K. L., Deeds, J. D., Acton, S. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4619 · Cited by 303
Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase
Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297
Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes.
Laakso, M., Lehto, S., Penttilä, I., & Pyörälà, K. (1993) · Circulation · doi:10.1161/01.cir.88.4.1421 · Cited by 301
Alcohol intake modulates the effect of a polymorphism of the cholesteryl ester transfer protein gene on plasma high density lipoprotein and the risk of myocardial infarction.
Fumeron, F., Betoulle, D., Luc, G., Behague, I., Ricard, S., Poirier, O., Jemaa, R., Evans, A., Arveiler, D., & Marques-Vidal, P. M. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118207 · Cited by 299
STATISTICAL METHODS FOR THE ANALYSIS OF HIGH-THROUGHPUT METABOLOMICS DATA
Bartel, J., Krumsiek, J., & Theis, F. J. (2013) · Computational and Structural Biotechnology Journal · doi:10.5936/csbj.201301009 · Cited by 307
Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice
Agellon, L. B., Walsh, A., Hayek, T., Moulin, P., Jiang, X., Shelanski, S. A., Breslow, J. L., & Tall, A. R. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99088-5 · Cited by 297
The Critical Role of Mast Cells in Allergy and Inflammation
Theoharides, T. C., & Kalogeromitros, D. C. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1366.025 · Cited by 293
Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients
Bloedon, L. T., Dunbar, R. L., Duffy, D., Pinell-Salles, P., Norris, R., DeGroot, B. J., Movva, R., Navab, M., Fogelman, A. M., & Rader, D. J. (2008) · Journal of Lipid Research · doi:10.1194/jlr.p800003-jlr200 · Cited by 296
Restoration of Endothelial Function by Increasing High-Density Lipoprotein in Subjects With Isolated Low High-Density Lipoprotein
Bisoendial, R. J., Hovingh, G. K., Levels, J. H. M., Lerch, P. G., Andresen, I., Hayden, M. R., Kastelein, J. J. P., & Stroes, E. S. G. (2003) · Circulation · doi:10.1161/01.cir.0000070934.69310.1a · Cited by 287
High-Density Lipoprotein Promotes Endothelial Cell Migration and Reendothelialization via Scavenger Receptor-B Type I
Seetharam, D., Mineo, C., Gormley, A. K., Gibson, L. L., Vongpatanasin, W., Chambliss, K. L., Hahner, L., Cummings, M. L., Kitchens, R. L., Marcel, Y. L., et al. (2005) · Circulation Research · doi:10.1161/01.res.0000199272.59432.5b · Cited by 282
HMG-CoA Reductase Inhibitors and Myotoxicity
Ucar, M., Mjörndal, T., & Dahlqvist, R. (2000) · Drug Safety · doi:10.2165/00002018-200022060-00003 · Cited by 279
“[23] It is synthesised from acetyl-CoA with de”
Background
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Institute of Medicine (2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 274
Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies
Krishna, R., Anderson, M. S., Bergman, A. J., Jin, B., Fallon, M. S., Côté, J., Rosko, K., Chavez-Eng, C. M., Lutz, R., Bloomfield, D. M., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61813-3 · Cited by 275
Liver-specific Overexpression of Scavenger Receptor BI Decreases Levels of Very Low Density Lipoprotein ApoB, Low Density Lipoprotein ApoB, and High Density Lipoprotein in Transgenic Mice
Wang, N., Arai, T., Ji, Y. I., Rinninger, F., & Tall, A. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32920 · Cited by 275
The ATP binding cassette transporter A1 (ABCA1) modulates the development of aortic atherosclerosis in C57BL/6 and apoE-knockout mice
Joyce, C. W., Amar, M. J., Lambert, G. C., Vaisman, B. L., Paigen, B. J., Najib-Fruchart, J., Hoyt, R. F., Neufeld, E. D., Remaley, A. T., Fredrickson, D. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012587699 · Cited by 269
Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene.
Hayek, T., Masucci-Magoulas, L., Jiang, X. L., Walsh, A., Rubin, E. M., Breslow, J. L., & Tall, A. R. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118255 · Cited by 265
Hepatic Scavenger Receptor BI Promotes Rapid Clearance of High Density Lipoprotein Free Cholesterol and Its Transport into Bile
Ji, Y. I., Wang, N., Ramakrishnan, R., Sehayek, E., Huszar, D., Breslow, J. L., & Tall, A. R. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.47.33398 · Cited by 263
Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis.
Zeiher, A. M., Schächlinger, V., Hohnloser, S. H., Saurbier, B., & Just, H. (1994) · Circulation · doi:10.1161/01.cir.89.6.2525 · Cited by 258
Genetic cholesteryl ester transfer protein deficiency caused by two prevalent mutations as a major determinant of increased levels of high density lipoprotein cholesterol.
Inazu, A., Jiang, X., Haraki, T., Yagi, K., KAMON, N., Koizumi, J., Mabuchi, H., Takeda, R., Takata, K., & Moriyama, Y. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117537 · Cited by 246
“Most prospective epidemiologic studies have shown that increased levels of HDL cholesterol (HDL-C') are an independent, negative risk factor for the development of coronary heart disease (CHD) (1).”
Background
Could targeted food taxes improve health?
Mytton, O. T., Gray, A. M., Rayner, M., & Rutter, H. (2007) · Journal of Epidemiology & Community Health · doi:10.1136/jech.2006.047746 · Cited by 244
The impact of phospholipid transfer protein (PLTP) on HDL metabolism
Huuskonen, J., Olkkonen, V. M., Jauhiainen, M., & Ehnholm, C. (2001) · Atherosclerosis · doi:10.1016/s0021-9150(01)00447-6 · Cited by 243
Endothelial Protection by High-Density Lipoproteins
Calabresi, L., Gomaraschi, M., & Franceschini, G. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000094961.74697.54 · Cited by 242
Differential Effects of Scavenger Receptor BI Deficiency on Lipid Metabolism in Cells of the Arterial Wall and in the Liver
Eck, M. V., Twisk, J., Hoekstra, M., Rij, B. T. V., van der Lans, C. A. C., Bos, I. S. T., Kruijt, J. K., Kuipers, F., & van Berkel, T. J. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m211233200 · Cited by 238
Effects of Recombinant Apolipoprotein A-I Milano on Aortic Atherosclerosis in Apolipoprotein E–Deficient Mice
Shah, P. K., Nilsson, J. Å., Kaul, S., Fishbein, M. C., Ageland, H., Hamsten, A., Johansson, J., Karpe, F., & Cercek, B. (1998) · Circulation · doi:10.1161/01.cir.97.8.780 · Cited by 238
Effects of Cholesteryl Ester Transfer Protein Inhibition on High-Density Lipoprotein Subspecies, Apolipoprotein A-I Metabolism, and Fecal Sterol Excretion
Brousseau, M. E., Diffenderfer, M. R., Millar, J. S., Nartsupha, C., Asztalos, B. F., Welty, F. K., Wolfe, M. L., Rudling, M. J., Björkhem, I., Angelin, B., et al. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000161928.16334.dd · Cited by 230
“These data indicate that partial inhibition of CETP via torcetrapib in patients with low HDL-C: (1) normalizes apoA-I levels within 1-migrating HDL, (2) increases plasma concentrations of HDL apoA-I by delaying apoA-I catabolism, and (3) does not significantly influence fecal sterol excretion.”
BackgroundInfluential
Lipid efflux by the ATP-binding cassette transporters ABCA1 and ABCG1
Cavelier, C., Lorenzi, I., Rohrer, L., & von Eckardstein, A. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.04.012 · Cited by 237
Structural models of human apolipoprotein A-I: a critical analysis and review
Brouillette, C. G., Anantharamaiah, G. M., Engler, J. A., & Borhani, D. W. (2001) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(01)00081-6 · Cited by 232
ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet
Terasaka, N., Yu, S., Yvan‐Charvet, L., Wang, N., Mzhavia, N., Langlois, R., Pagler, T. A., Li, R., Welch, C. L., Goldberg, I. J., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35470 · Cited by 232
Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-induced atherosclerosis.
Hoeg, J. M., Santamarina-Fojo, S., Bérard, A. M., Cornhill, J. F., Herderick, E. E., Feldman, S. H., Haudenschild, C. C., Vaisman, B. L., Hoyt, R. F., Demosky, S. J., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.21.11448 · Cited by 230
The role of hepatic lipase in lipoprotein metabolism and atherosclerosis
Santamarina-Fojo, S., Haudenschild, C., & Amar, M. J. (1998) · Current Opinion in Lipidology · doi:10.1097/00041433-199806000-00005 · Cited by 229
A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderly
Curb, J. D., Abbott, R. D., Rodríguez, B. L., Masaki, K., Chen, R., Sharp, D. S., & Tall, A. R. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300520-jlr200 · Cited by 228
“Combined results from four large observational studies indicated that a 1 mg/dl increment in HDL-C was associated with approximately a 2% to 3% decrease in the risk of coronary artery disease in middle-aged individuals (3).”
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227
Novel Biological Functions of High-Density Lipoprotein Cholesterol
Mineo, C., & Shaul, P. W. (2012) · Circulation Research · doi:10.1161/circresaha.111.258673 · Cited by 237
Prevalence of risk factors in men with premature coronary artery disease
Genest, J. J., McNamara, J. R., Salem, D. N., & Schaefer, E. J. (1991) · The American Journal of Cardiology · doi:10.1016/0002-9149(91)90924-a · Cited by 243

Authors: Desforges, J. F., Gordon, D. J., & Rifkind, B. M.
Affiliations: National Heart, Lung, and Blood Institute (US)
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 1989-11-09
Volume: 321
Issue: 19
Pages: 1311-1316
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm198911093211907
OpenAlex: W2339616051
Cited by: 1,547
References: 50
Citations by year: 2026: 9 · 2025: 6 · 2024: 15 · 2023: 19 · 2022: 13 · 2021: 22 · 2020: 22 · 2019: 30 · 2018: 21 · 2017: 24 · 2016: 36 · 2015: 47 · 2014: 42 · 2013: 42 · 2012: 38
FWCI: 9.17
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: high-density lipoprotein, HDL cholesterol, coronary artery disease, atherogenesis, cardioprotection, HDL metabolism, Helsinki Heart Study
MeSH terms: Coronary Disease, Humans, Lipoproteins, HDL, Cholesterol, HDL

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

High-Density Lipoprotein — The Clinical Implications of Recent Studies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks